Compugen Ltd. Aktie News

HOLON, Israel, 22. Sept. 2026 /PRNewswire/ -- Compugen Ltd.

Die MAIA-ovarian-Studie mit COM701 verläuft planmäßig; medianes progressionsfreies Überleben aus der Zwischenanalyse wird bis Q1 2027 erwartet. Poster zu laufender MAIA-ovarian-Studie auf dem ESMO Gynaecological Cancers Congress 2026 präsentiert, was die biologische und klinische Begründung für die Untersuchung von COM701 bei platin-sensitivem Ovarialkarzinom stärkt. Partner AstraZeneca stellte...

HOLON, Israel, 21. Juli 2026 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN) (TASE: CGEN), ein im klinischen Stadium befindliches Krebsimmuntherapie-Unternehmen und Pionier in der computergestützten Zielentdeckung mit AI/ML, gab heute bekannt, dass das Management auf der BTIG Biotechnology Conference 2026 präsentieren und 1x1-Meetings abhalten wird; die Konferenz findet virtuell vom 28.–29. Juli 2...

HOLON, Israel, June 18, 2026 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational drug target discovery powered by AI/ML, today presented a trial-in-progress poster on the MAIA-ovarian adaptive platform trial of COM701, a potential first-in-class anti-PVRIG antibody, at the ESMO Gynaecological Cancers Congress 202...

HOLON, Israel, June 8, 2026 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery powered by AI/ML, today announced that management will participate in Jones Trading's Mapping the Path from Target to Patient: Fireside Chat Series with Leaders in AI/ ML-based Drug Development on Monday, June 15, 202...

COM701 MAIA-ovarian trial actively enrolling patients across all clinical sites in the U.S., Israel, and France; interim analysis on track by Q1 2027 Partner AstraZeneca is advancing rilvegostomig across 11 ongoing Phase 3 trials and presented clinical and pre-clinical rilvegostomig data at AACR 2026, including late-breaking Phase 2 data in HER2-positive gastric cancer (DESTINY-Gastric03), with...

HOLON, Israel, May 12, 2026 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery powered by AI/ML, today announced that management will present at the 2026 Stifel Virtual Targeted Oncology Forum.